Year:
2026
Region / city:
USA, Austria, Norway, Brazil, Canada, Colombia, Denmark, UK, Australia
Subject:
Human papillomavirus vaccine, Cervical cancer prevention
Document Type:
Clinical trial report
Organization / institution:
Multiple research institutions and hospitals
Authors:
Warner K. Huh, Elmar A. Joura, Anna R. Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A. Ault, Deborah Bartholomew, Ramon M. Cestero, Edison N. Fedrizzi, Angelica L. Hirschberg, Marie-Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T. Stapleton, Dorothy J. Wiley, Alex Ferenczy, Robert Kurman, Brigitte M. Ronnett, Mark H. Stoler, Jack Cuzick, Suzanne M. Garland, Susanne K. Kjaer, Oliver M. Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C. Roberts, Christine Shields, Alain Luxembourg
Target Audience:
Healthcare professionals, Researchers, Public health policymakers
Period of validity:
6 years
Approval date:
2026
Date of changes:
2026
Keywords:
human papillomavirus, vaccine, cervical cancer, persistent infection, cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia
Funding:
Merck & Co., Inc., Kenilworth, NJ, USA
Clinical trial registration:
NCT00543543 (https://clinicaltrials.gov/ct2/show/NCT00543543
Note:
)
Word count:
4963/4500
References:
30/30
Contextual description:
This clinical trial report presents the long-term efficacy, immunogenicity, and safety outcomes of a nine-valent HPV vaccine for preventing HPV-related cervical diseases in young women.
